© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
September 16, 2021
A team of investigators have found that a molecular mechanism that drives the progression of uveal melanoma, an often lethal eye cancer in adults.
September 13, 2021
AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
September 10, 2021
José-Alain Sahel, MD, explains how optogenetics involves artificial photoreceptors from specific retinal cells to restore vision.
September 09, 2021
The gene-based AAVCOVID vaccine employs a unique adeno-associated viral vector technology that was shown in non-clinical, nonhuman primate studies to enable protection from SARS-CoV-2 challenge and to induce sustained antibody and cellular immune responses from a single dose for up to a year.
September 07, 2021
Development of new animal model enhances study of potential mutations.
September 03, 2021
Study examines immunomodulatory therapy as a potential long-term treatment option.
August 30, 2021
In PIONEER study, investigators outline their successes.
August 18, 2021
GT005 designed to induce local production of recombinant complement factor I.
August 17, 2021
CAM’s regenerative healing means long-term relief and fewer visits to clinic.
August 13, 2021
Cotargeted therapy could help combat inherited retinal diseases.
